Logo image of LUCD

LUCID DIAGNOSTICS INC (LUCD) Stock Fundamental Analysis

NASDAQ:LUCD - Nasdaq - US54948X1090 - Common Stock - Currency: USD

1.29  -0.02 (-1.53%)

After market: 1.2732 -0.02 (-1.3%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to LUCD. LUCD was compared to 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of LUCD have multiple concerns. LUCD is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LUCD has reported negative net income.
LUCD had a negative operating cash flow in the past year.
In the past 5 years LUCD always reported negative net income.
LUCD had a negative operating cash flow in each of the past 5 years.
LUCD Yearly Net Income VS EBIT VS OCF VS FCFLUCD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of LUCD (-216.30%) is worse than 93.62% of its industry peers.
Industry RankSector Rank
ROA -216.3%
ROE N/A
ROIC N/A
ROA(3y)-179.51%
ROA(5y)-192.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LUCD Yearly ROA, ROE, ROICLUCD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LUCD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LUCD Yearly Profit, Operating, Gross MarginsLUCD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -5K -10K

More info and screens

0

2. Health

2.1 Basic Checks

LUCD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LUCD has been increased compared to 1 year ago.
LUCD has more shares outstanding than it did 5 years ago.
LUCD has a better debt/assets ratio than last year.
LUCD Yearly Shares OutstandingLUCD Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
LUCD Yearly Total Debt VS Total AssetsLUCD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -13.02, we must say that LUCD is in the distress zone and has some risk of bankruptcy.
LUCD has a Altman-Z score of -13.02. This is amonst the worse of the industry: LUCD underperforms 85.11% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.02
ROIC/WACCN/A
WACC8.45%
LUCD Yearly LT Debt VS Equity VS FCFLUCD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 0.75 indicates that LUCD may have some problems paying its short term obligations.
LUCD's Current ratio of 0.75 is on the low side compared to the rest of the industry. LUCD is outperformed by 92.55% of its industry peers.
A Quick Ratio of 0.74 indicates that LUCD may have some problems paying its short term obligations.
LUCD's Quick ratio of 0.74 is on the low side compared to the rest of the industry. LUCD is outperformed by 89.36% of its industry peers.
Industry RankSector Rank
Current Ratio 0.75
Quick Ratio 0.74
LUCD Yearly Current Assets VS Current LiabilitesLUCD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.28% over the past year.
Looking at the last year, LUCD shows a very strong growth in Revenue. The Revenue has grown by 39.99%.
Measured over the past years, LUCD shows a very strong growth in Revenue. The Revenue has been growing by 105.61% on average per year.
EPS 1Y (TTM)3.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30%
Revenue 1Y (TTM)39.99%
Revenue growth 3Y105.61%
Revenue growth 5YN/A
Sales Q2Q%-17.28%

3.2 Future

LUCD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.09% yearly.
The Revenue is expected to grow by 87.84% on average over the next years. This is a very strong growth
EPS Next Y42.61%
EPS Next 2Y30.68%
EPS Next 3Y23.2%
EPS Next 5Y12.09%
Revenue Next Year78.75%
Revenue Next 2Y136.7%
Revenue Next 3Y106.69%
Revenue Next 5Y87.84%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
LUCD Yearly Revenue VS EstimatesLUCD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
LUCD Yearly EPS VS EstimatesLUCD Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LUCD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUCD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUCD Price Earnings VS Forward Price EarningsLUCD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUCD Per share dataLUCD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as LUCD's earnings are expected to grow with 23.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.68%
EPS Next 3Y23.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LUCD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LUCID DIAGNOSTICS INC

NASDAQ:LUCD (6/13/2025, 8:18:37 PM)

After market: 1.2732 -0.02 (-1.3%)

1.29

-0.02 (-1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners5.47%
Inst Owner Change183.35%
Ins Owners8.08%
Ins Owner Change6.95%
Market Cap139.57M
Analysts83.33
Price Target3.83 (196.9%)
Short Float %2.51%
Short Ratio1.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-108.03%
Min EPS beat(2)-223.17%
Max EPS beat(2)7.12%
EPS beat(4)1
Avg EPS beat(4)-57.49%
Min EPS beat(4)-223.17%
Max EPS beat(4)7.12%
EPS beat(8)3
Avg EPS beat(8)-32.99%
EPS beat(12)5
Avg EPS beat(12)-20.36%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-27.13%
Min Revenue beat(2)-36.75%
Max Revenue beat(2)-17.51%
Revenue beat(4)1
Avg Revenue beat(4)-18.86%
Min Revenue beat(4)-36.75%
Max Revenue beat(4)0.77%
Revenue beat(8)1
Avg Revenue beat(8)-20.24%
Revenue beat(12)2
Avg Revenue beat(12)-25.84%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.25%
EPS NQ rev (1m)9.16%
EPS NQ rev (3m)14.45%
EPS NY rev (1m)-4.36%
EPS NY rev (3m)10.99%
Revenue NQ rev (1m)-21.41%
Revenue NQ rev (3m)-29.65%
Revenue NY rev (1m)-7.84%
Revenue NY rev (3m)-25.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 33.44
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.04
BVpS-0.05
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -216.3%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-179.51%
ROA(5y)-192.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 79.14%
Cap/Sales 16.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.75
Quick Ratio 0.74
Altman-Z -13.02
F-Score4
WACC8.45%
ROIC/WACCN/A
Cap/Depr(3y)37.04%
Cap/Depr(5y)N/A
Cap/Sales(3y)87.81%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30%
EPS Next Y42.61%
EPS Next 2Y30.68%
EPS Next 3Y23.2%
EPS Next 5Y12.09%
Revenue 1Y (TTM)39.99%
Revenue growth 3Y105.61%
Revenue growth 5YN/A
Sales Q2Q%-17.28%
Revenue Next Year78.75%
Revenue Next 2Y136.7%
Revenue Next 3Y106.69%
Revenue Next 5Y87.84%
EBIT growth 1Y-6.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.14%
EBIT Next 3Y3.6%
EBIT Next 5Y7.06%
FCF growth 1Y-40.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.1%
OCF growth 3YN/A
OCF growth 5YN/A